February 2022

Read up on essential news

We want to keep you informed. Here are a few important news items and reminders for you this month.

Changes to our National Precertification List (NPL)

The following new-to-market drugs require precertification

- Susvimo™ (ranibizumab injection) — Precertification is required effective February 1, 2022. This drug is part of the ophthalmic medical injectables drugs category.
- Cortrophin™ Gel (repository corticotropin injection) — Precertification is required effective February 9, 2022.

Submitting precertification requests

Be sure to submit precertification requests at least two weeks in advance. To save time, request precertification online. Doing so is fast, secure and simple.

You can submit most requests online through our Availity provider portal.* Or you can use your practice’s Electronic Medical Record (EMR) system if it’s set up for electronic precertification requests. Use our “Search by CPT code” search function on our precertification lists page to find out if the code requires precertification.

Learn more about precertification.

Are you asking for precertification on a specialty drug for a commercial or Medicare member? Then submit your request through
Novologix®, also available on Availity. Not registered for Availity®? Go to Availity to register and learn more.

These changes apply to our commercial and Medicare members.

*Availity is available only to U.S. providers and its territories.

**Site-of-service precertification requirements**

In the September 2021 OfficeLink Updates™ newsletter, we announced that our site-of-service precertification requirements for outpatient surgical procedures would become effective on December 1, 2021.

We want to add that these requirements currently apply only to our fully insured, commercial line of business.

For a listing of codes that require site-of-service review, please see our National Participating Provider Precertification List (PDF).

**COVID-19 testing**

We cover COVID-19 testing without cost sharing when medically necessary. We do not cover testing for returning to work or school, or for surveillance purposes or travel purposes. The patient is responsible for the full cost of testing if the billed place of service is work or school.

You can read more about COVID-19 testing on our Testing and Treatment page.

These changes apply to our commercial and Medicare members.